Synthetic growth-hormone secretagogue receptor agonist
PRODUCT PROFILE
GHRP-2
£44.00
GHRP-2 is synthetic growth-hormone secretagogue receptor agonist. Researchers examine it in relation to acute gh secretion, ghrelin-pathway pharmacology and pituitary testing.
Why it is distinct
Typically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
- Evidence stageEarly human evidence
- AvailabilityUnavailable
- Batch recordPublished after verification
- DispatchConfirmed at checkout
Out of stock
Ask about availabilityPRODUCT INFORMATION
Clear first. Detailed when needed.
What this material is+
GHRP-2 is synthetic growth-hormone secretagogue receptor agonist. Researchers examine it in relation to acute gh secretion, ghrelin-pathway pharmacology and pituitary testing.
Research focus+
Researchers study its ability to cause a short rise in growth hormone and its wider effects on pituitary signalling. It is mainly a research tool rather than an authorised treatment.
How the mechanism differs+
Activates GHSR-1a and can influence GH plus other neuroendocrine signals depending on exposure.
Evidence and limitations+
Human challenge and diagnostic studies exist, but it has no broadly established therapeutic indication.
Testing and batch documentation+
No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.
RESEARCH PROFILE
Understand the distinction.
Researchers study its ability to cause a short rise in growth hormone and its wider effects on pituitary signalling. It is mainly a research tool rather than an authorised treatment.
Activates GHSR-1a and can influence GH plus other neuroendocrine signals depending on exposure.
Typically characterised as a strong GH secretagogue with less appetite emphasis than GHRP-6.
Human challenge and diagnostic studies exist, but it has no broadly established therapeutic indication.
Educational research context only. This information is not dosage, administration or personal-use guidance.
CONTINUE EXPLORING
Related research perspectives.
Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.
-
Experimental
Follistatin 344
£76.001 mgBatch file pendingA ligand-binding inhibitor of the activin/myostatin system, not a GH or IGF secretagogue.
UnavailableAsk about availability -
Early human evidence
CJC-1295 No DAC
Price range: £25.99 through £32.995 mgBatch file pendingShort-duration GHRH signalling, in contrast with albumin-bound, long-acting CJC-1295 DAC.
UnavailableAsk about availability This product has multiple variants. The options may be chosen on the product page -
Established
Sermorelin
£49.005 mgBatch file pendingClosest to the natural active GHRH sequence and shorter acting than tesamorelin or CJC-1295 DAC.
UnavailableAsk about availability -
Early human evidence
Hexarelin
£51.005 mgBatch file pendingA potent older GHRP with less hormonal selectivity than ipamorelin.
UnavailableAsk about availability